The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

The approval relies on positive data from the POTOMAC Phase III trial.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

AstraZeneca (AZN) stock is in focus as the FDA approves a label expansion for its breast cancer therapy Truqap in prostate ...

AstraZeneca's drug Truqap in combination with two other medications secured approval for the treatment of a form of advanced prostate cancer by the Food and Drug Administration. Approval was based on ...

Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...

PARIS — A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to ...

AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of ​its ...